Study of the compound RCS-21 on the safety of healthy volunteers, its tolerability and on the way the body absorbs, distributes, and gets rid of this drug.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512351-21-00

Acronym

RNATICS-2401

Enrollment

Registered

2024-11-08

Start date

2024-12-10

Completion date

Unknown

Last updated

2025-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Safety, tolerability and pharmacokinetics of single-ascending doses of RCS-21 in healthy volunteers (AMIR-21)

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026